Surveillance of chemotherapy in lung cancer patients on hemodialysis
Not Applicable
- Conditions
- advanced lung cancer patients with end-stage kidney disease on hemodialysis
- Registration Number
- JPRN-UMIN000036280
- Lead Sponsor
- Specified Nonprofit Corporation North East Japan Study Group
- Brief Summary
Chemotherapy should be considered for hemodialysis patients with EGFR-mutant NSCLC and SCLC. However, the survival benefits of chemotherapy for NSCLC patients with EGFR-wild type are unclear; physicians should carefully consider whether to offer chemotherapy to this patient subset.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 162
Inclusion Criteria
Not provided
Exclusion Criteria
Patient, or family refuses to participate in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method frequency of severe adverse event
- Secondary Outcome Measures
Name Time Method overall survival objective response rate time to treatment failure frequency of each adverse events type of anti-cancer drugs